Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
出版年份 2018 全文链接
标题
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 102, Issue 2, Pages 163-173
出版商
Wiley
发表日期
2018-10-23
DOI
10.1111/ejh.13188
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
- (2018) Jay H. Kalin et al. Nature Communications
- EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
- (2017) Kyriaki Tzogani et al. ONCOLOGIST
- Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
- (2017) Roberta Mazzone et al. Clinical Epigenetics
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach
- (2016) Elliot M. Epner et al. EXPERIMENTAL HEMATOLOGY
- How do tumor cells respond to HDAC inhibition?
- (2016) Andrea Newbold et al. FEBS Journal
- The molecular hallmarks of epigenetic control
- (2016) C. David Allis et al. NATURE REVIEWS GENETICS
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- (2015) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
- (2015) S. P. Iyer et al. ONCOLOGIST
- Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
- (2015) Stuart Gallagher et al. Cancers
- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
- (2014) Zhiming Li et al. International Journal of Biological Sciences
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
- (2013) Benjamin E. L. Lauffer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
- (2011) K Ted Thurn et al. Future Oncology
- HDAC family: What are the cancer relevant targets?
- (2008) Olaf Witt et al. CANCER LETTERS
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
- (2008) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now